8-KOther Events

JOHNSON & JOHNSON 8-K Report, Corporate Update (Jul 17, 2006)

Filed July 17, 2006For Securities:JNJ

Summary

Johnson & Johnson announced on July 17, 2006, through its subsidiary Cordis Corporation, the acquisition of Ensure Medical, Inc. This acquisition brings a novel investigational technology for post-catheterization femoral artery closure. The technology utilizes a synthetic bioabsorbable polymer, offering a potential advancement in medical device solutions for patients undergoing arterial procedures. For investors, the key takeaway is J&J's continued strategic investment in expanding its medical device portfolio with innovative technologies. While the acquisition is expected to result in a one-time after-tax charge of approximately $52 million, or $0.02 per share, related to in-process research and development, this is a standard practice for integrating early-stage technologies. The long-term value creation from this acquisition will depend on the successful development and commercialization of the acquired femoral artery closure device.

Key Highlights

  • 1Cordis Corporation, a Johnson & Johnson company, has acquired Ensure Medical, Inc.
  • 2Ensure Medical, Inc. develops devices for post-catheterization closure of the femoral artery.
  • 3The acquired technology uses a synthetic bioabsorbable polymer for bleeding control and puncture site closure.
  • 4The acquisition is expected to result in a one-time after-tax charge of approximately $52 million.
  • 5This charge equates to an estimated $0.02 per share.
  • 6The charge is attributed to the expensing of in-process research and development.
  • 7Other transaction terms were not disclosed.

Frequently Asked Questions

The acquisition of Ensure Medical, Inc. is strategically important as it allows Johnson & Johnson, through Cordis Corporation, to enhance its medical device offerings in the cardiovascular space. The acquired technology for femoral artery closure addresses a critical need post-catheterization, potentially improving patient outcomes and procedural efficiency.

In the short term, the acquisition is expected to result in a one-time after-tax charge of approximately $52 million, or $0.02 per share. This charge is due to the accounting treatment for in-process research and development, which is common when acquiring early-stage technologies.

The long-term value will depend on the successful development and commercialization of Ensure Medical's investigational femoral artery closure device. If the technology proves effective and gains market adoption, it could represent a significant addition to Cordis's product line and contribute positively to future revenue and profitability.

Yes, the filing explicitly states that other terms of the transaction were not disclosed, which is common in many acquisition agreements where sensitive financial or strategic details are kept confidential.